British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...

Italy's Industry Minister Adolfo Urso on Thursday told parliament that Rome would ask the European Union to immediately ...

However, Pfizer and Moderna's revenue and earnings dropped significantly once the pandemic receded, as did their share prices ...

The long-acting Respiratory Syncytial Virus (RSV) immunisation is now available free for eligible families until September 30 ...

The latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of ...

Pfizer’s RSV vaccine Abrysvo receives European approval to help protect adults aged 18-59 against RSV lower respiratory tract disease: New York Wednesday, April 2, 2025, 09:00 H ...

Pfizer's latest plot twist includes an expanded European nod for its RSV vaccine, ABRYSVO, and a new autoimmune collab with ...

Pfizer (NYSE:PFE) recently saw the European Commission expand the authorization for its RSV vaccine, ABRYSVO, to include younger adults, and announced a collaboration with Flagship Pioneering for ...

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO®, the ...

Pfizer (PFE) announced that the European Commission has issued a decision amending the marketing authorization for Abrysvo, the company’s ...

Pfizer’s respiratory syncytial virus (RSV) vaccine has been approved by the European Commission (EC) to prevent RSV-associated lower respiratory tract disease (LRTD) in individuals aged 18 to 59 years ...

Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation ...